DDInter1725 DDInter1376
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Sulfasalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Balsalazide
Sulfasalazine {u} (Compound) treats {v} (Disease) ankylosing spondylitis
Sulfasalazine {u} (Compound) binds {v} (Gene) SLC46A1
Sulfasalazine {u} (Compound) upregulates {v} (Gene) GPATCH8
Sulfasalazine {u} (Compound) is included by {v} (Pharmacologic Class) Aminosalicylic Acids
Sulfasalazine {u} (Compound) downregulates {v} (Gene) ITGAE
Sulfasalazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levomefolic acid
Sulfasalazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Folic acid
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Sulfasalazine (Compound) resembles Olsalazine (Compound)
Sulfasalazine (Compound) resembles Balsalazide (Compound)
Sulfasalazine (Compound) treats ankylosing spondylitis (Disease)
Sulfasalazine (Compound) binds SLC46A1 (Gene)
Sulfasalazine (Compound) upregulates GPATCH8 (Gene)
Sulfasalazine (Compound) is included by Aminosalicylic Acids (Pharmacologic Class)
Sulfasalazine (Compound) downregulates ITGAE (Gene)
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Levomefolic acid
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Folic acid
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli